STOCK TITAN

Kardigan (KARD) Stock Price, News & Analysis

KARD NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
17 67 sessions, June 18, 2026 to September 23, 2026
Largest daily move
+11.8% close of September 2, 2026

Company Description

Kardigan (NASDAQ: KARD) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $1.4B.

KARD has declined 30.9% over the past month. The last closing price was $14.52.

This page collects what Stock Titan holds for KARD, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

$14.73
-10.40%
1.71
Last updated: September 23, 2026 at 18:27
-30.9%
Performance 1 month

Kardigan (KARD) closed at $14.52 on September 23, 2026. Over the past month, the price has lost 30.9%.

See what a $1,000 investment in KARD would be worth today

KARD Metrics & Rankings

Price returns through September 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

Kardigan has 4 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 2 with negative movement. Key topics include earnings, IPO, offering. View all KARD news →

Financial Highlights

Revenue (latest FY)
Net Income (latest FY)
Operating Cash Flow

Upcoming Events

JAN
01
January 1, 2027 - June 30, 2027 Clinical

Danicamtiv topline data

Topline readout for KINSHIP-DCM Phase 2b (danicamtiv) targeted in 1H 2027; no specific date yet; material to program outlook.
JAN
01
January 1, 2027 - June 30, 2027 Clinical

Ataciguat topline data

Topline readout for KATALYST-AV Phase 2b (ataciguat) targeted in 1H 2027; timing to affect clinical progression and guidance.
JAN
01
January 1, 2027 - June 30, 2027 Clinical

Tonlamarsen topline data

Topline readout for KARDINAL-ASH Phase 2 (tonlamarsen) targeted in 1H 2027; no firm date provided; could influence valuation.

Kardigan has 3 upcoming scheduled events. The next event, "Danicamtiv topline data", is scheduled for January 1, 2027 (in 98 days). Investors can track these dates to stay informed about potential catalysts that may affect the KARD stock price.

Short Interest History

Last 12 Months

Short interest in Kardigan (KARD) currently stands at 2.2 million shares, up 14.0% from the previous reporting period, representing 4.1% of the float. Since June 2026, short interest has increased by 50.3%. This relatively low short interest suggests limited bearish sentiment. The 9.1 days to cover indicates moderate liquidity for short covering.

Days to Cover History

Last 12 Months

Days to cover for Kardigan (KARD) currently stands at 9.1 days. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 574.8% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.4 to 9.3 days.

KARD Company Profile & Sector Positioning

Kardigan (KARD) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Frequently Asked Questions

What is the current stock price of Kardigan (KARD)?

The current stock price of Kardigan (KARD) is $14.73 as of September 23, 2026.

What is the market cap of Kardigan (KARD)?

The market cap of Kardigan (KARD) is approximately $1.4B. Learn more about what market capitalization means .